Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
Fen Liu, Guisen Yin, Shuyi Xue, Faisal UL Rehman, Dehua Liao, Yong Pan
Abstract
Hematological and respiratory toxicity of T-DXd and hepatobiliary toxicity of T-DM1 exhibited a high incidence of fatal outcomes. It is crucial to identify high-risk factors and enhance the monitoring of AEs during clinical application.
Topics & Concepts
Adverse Event Reporting SystemMedicineAdverse effectInternal medicinePostmarketing surveillancePharmacovigilanceOdds ratioTrastuzumab emtansineAntibody-drug conjugateOncologyTrastuzumabBreast cancerImmunologyCancerAntibodyMonoclonal antibodyHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies